Innogenetics
VC Fund
Gent, Belgium
Innogenetics is a VC fund in Gent focused on Biotechnology and Manufacturing. Innogenetics NV develops and markets diagnostic products for therapy management and patient health. Its diagnostics business focuses on developing products for infectious diseases, genetic testing, tissue typing, neurodegeneration, and oncology. Its products in the area of infectious diseases include screening and confirmation tests for HIV, HCV,HTLV, and syphilis; genotyping tests for hepatitis B virus (HBV), human papillomavirus, and mycobacterium sp; and drug-resistance tests for TB and HBV. Innogenetics also offers genetic testing products comprising detection tests for cystic fibrosis, as well as MBL2 and APO E genetic variants associated with genetic risks; tissue typing tests to determine the type of HLA; and neurodegeneration products, which include tests for Alzheimer's disease. In the Oncology area, the company distributes AdnaGen AG’s diagnostics products for breast and colon cancer. Its therapeutics business engages in the development of therapeutic vaccines for the treatment of infectious diseases caused by hepatitis C, hepatitis B, and human papillomaviruses. The company’s therapeutic portfolio includes GNI-102, a polyepitope vaccine candidate, which is in phase I clinical trial targeting HBV; GNI-104, which are anti-HCV neutralizing human monoclonal antibodies; and GNI-105, a HPV polyepitope vaccine candidate. It has collaborative research, development, distribution, or licensing agreements with Solvay Pharmaceuticals BV; sanofi-aventis; Takeda Chemical Industries; Immuno-Biological Laboratories Co; Roche Group of companies; AdnaGen AG; Siemens Healthcare Diagnostics; Danisco A/S; Pharmexa-Epimmune, Inc.; and PamGene International BV. It sells its products primarily in Germany, Italy, France, Spain, the United States, Brazil, Switzerland, Austria, the Benelux, and Eastern Europe. It was founded in 1985 and is based in Gent, Belgium. As of November 20, 2008, Innogenetics NV operates as a subsidiary of Solvay Pharmaceuticals S.A.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Innogenetics invests in
Stages Innogenetics invests in
Countries Innogenetics invests in
Investment Focus
Industry
- Biotechnology 1 (100%)
- Manufacturing 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CellTran
|
CellTran Limited engages in the research and development of products for the regeneration of tissue and the healing of wounds. The company offers Myskin that is used for the treatment of difficult to heal wounds; Lyphoderm, a freeze-dried lysate from cultured human keratinocytes that is formulated into a hydrophilic gel; and Ulcodress, anintegrated wound care dressing that provides control of moisture, infection, and proteases within the wound area. It provides skin banking services, as well as contract manufacture services in the fields of materials fabrication and cell culture. The company was founded in 2000 and is based in Sheffield, the United Kingdom. As of October 28, 2008, CellTran Limited operates as a subsidiary of York Pharma plc. | $1.3M / Aug 21, 2007 |
Co-Investors
PUK Ventures
1 deal together
South Yorkshire Investment Fund
1 deal together
White Rose Technology Seedcorn Fund
1 deal together
YFM Equity Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Innogenetics invest in?
Innogenetics invests primarily in Biotechnology and Manufacturing startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Innogenetics last invest?
The most recent investment recorded for Innogenetics closed in Aug 2007. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
